The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
HDL biogenesis and functions: Role of HDL quality and quantity in atherosclerosis
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Virmani, R., Kolodgie, F. D., Burke, A. P., Farb, A., & Schwartz, S. M. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.5.1262 · Cited by 4,084
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency
Brooks-Wilson, A., Marcil, M., Clee, S. M., Zhang, L.-H., Roomp, K., van Dam, M., Yu, L., Brewer, C., Collins, J. A., Molhuizen, H. O. F., et al. (1999) · Nature Genetics · doi:10.1038/11905 · Cited by 1,687
High-Density Lipoprotein — The Clinical Implications of Recent Studies
Desforges, J. F., Gordon, D. J., & Rifkind, B. M. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911093211907 · Cited by 1,547 · cited 1×
“In addition, other studies in humans showed that n increase in plasma HDL levels correlated with slower progresion of atherosclerotic lesions and possible stabilization of unstable therosclerotic plaques [90,94].”
Antiinflammatory Properties of HDL
Barter, P. J., Nicholls, S., Rye, K.-A., Anantharamaiah, G. M., Navab, M., & Fogelman, A. M. (2004) · Circulation Research · doi:10.1161/01.res.0000146094.59640.13 · Cited by 1,394
One-year cardiovascular event rates in outpatients with atherothrombosis
Steg, P. G., Bhatt, D. L., Wilson, P. W. F., D’Agostino, R., Ohman, E. M., Röther, J., Liau, C.-S., Hirsch, A. T., Mas, J.-L., Ikeda, Y., et al. (2007) · JAMA · doi:10.1001/jama.297.11.1197 · Cited by 1,382 · cited 1×
“[3] Steg PG, Bhatt DL, Wilson PW, et al.”
Manninen, V, Tenkanen, L., Koskinen, P., Huttunen, J. K., Mänttäri, M., Heinonen, O. P., & Frick, M. H. (1992) · Circulation · doi:10.1161/01.cir.85.1.37 · Cited by 1,329
Vaisar, T., Pennathur, S., Green, P. S., Gharib, S. A., Hoofnagle, A. N., Cheung, M. C., Byun, J., Vuletic, S., Kassim, S., Singh, P., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci26206 · Cited by 942 · cited 1×
“[65] Vaisar T, Pennathur S, Green PS, et al.”
Neaton, J. D. (1992) · Archives of Internal Medicine · doi:10.1001/archinte.1992.00400130082009 · Cited by 784 · cited 1×
“has been isolated as the main cause of cardiovascular disease [5,6].”
Zannis, V. I., & Breslow, J. L. (1981) · Biochemistry · doi:10.1021/bi00507a059 · Cited by 563
Intestinal ABCA1 directly contributes to HDL biogenesis in vivo
Brunham, L. R. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27352 · Cited by 519 · cited 2×
“In the early steps of HDL formation, lipid-free apolipoprotein A-I which is secreted both by the liver (about 70% of apoA-I) [34] and the intestine (about 30% of apoA-I) [35], interacts with the lipid transporter ABCA1 and acquires phospholipid and cholesterol (Fig.”
Timmins, J. M., Lee, J.-Y., Boudyguina, E., Kluckman, K. D., Brunham, L. R., Mulya, A., Gebre, A. K., Coutinho, J. M., Colvin, P. L., Smith, T. L., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23915 · Cited by 447 · cited 2×
“In the early steps of HDL formation, lipid-free apolipoprotein A-I which is secreted both by the liver (about 70% of apoA-I) [34] and the intestine (about 30% of apoA-I) [35], interacts with the lipid transporter ABCA1 and acquires phospholipid and cholesterol (Fig.”
Kypreos, K. E., & Zannis, V. I. (2007) · Biochemical Journal · doi:10.1042/bj20061048 · Cited by 90 · cited 2×
“Using denovirus-mediated gene transfer in apoA-I-deficient mice (apoA−/−) or ABCA1-deficient mice (ABCA1−/−) [39] we established that poE interacts with ABCA1 and forms discoidal HDL particles in”
Self-citationApolipoprotein E Is Resistant to Intracellular Degradation in Vitro and in Vivo
Rensen, P. C. N., Jong, M. C., van Vark, L. C., van der Boom, H., Hendriks, W. L., van Berkel, T. J. C., Biessen, E. A. L., & Havekes, L. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8564 · Cited by 86
Probing the pathways of chylomicron and HDL metabolism using adenovirus-mediated gene transfer
Zannis, V. I., Chroni, A., Kypreos, K. E., Kan, H.-Y., Cesar, T. B., Zanni, E. E., & Kardassis, D. (2004) · Current Opinion in Lipidology · doi:10.1097/00041433-200404000-00008 · Cited by 74
Self-citationApolipoprotein E isoform‐specific binding to the low‐density lipoprotein receptor
Yamamoto, T., Choi, H. W., & Ryan, R. O. (2008) · Analytical Biochemistry · doi:10.1016/j.ab.2007.09.005 · Cited by 59 · cited 1×
“In vitro and in ivo studies have shown that lipoprotein-bound apoE is the natual ligand for the LDL-receptor [43,44], which is the main receptor nvolved in the clearance of apoE-containing lipoproteins in vivo 45].”
Linton, M. F., & Fazio, S. (1999) · Current Opinion in Lipidology · doi:10.1097/00041433-199904000-00003 · Cited by 51 · cited 2×
“[52] Linton MF, Fazio S.”
Cited by
Habauzit, V., & Morand, C. (2012) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622311430006 · Cited by 261
Kones, R. (2011) · Drug Design, Development and Therapy · doi:10.2147/dddt.s14934 · Cited by 259
High-density lipoprotein (HDL) metabolism and bone mass
Papachristou, N. I., Blair, H. C., Kypreos, K. E., & Papachristou, D. J. (2017) · Journal of Endocrinology · doi:10.1530/joe-16-0657 · Cited by 94
Self-citation
Metadata
- Authors
- Tsompanidi, E. M., Brinkmeier, M. S., Fotiadou, E. H., Giakoumi, S. M., & Kypreos, K. E.
- Venue
- Atherosclerosis
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 208
- Issue
- 1
- Pages
- 3-9
- ISSN
- 0021-9150 (ISSN-L)
- OpenAlex
- W2062311485
- Cited by
- 170
- References
- 19
- FWCI
- 14.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.